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Letter to the Editor
Re. Review Article entitled `The neoplastic pathogenesis
of solitary and multiple osteochondromas'
In a recent Review Article, Porter and Simpson
summarize the many theories proposed over the years
to explain the pathogenesis of osteochondroma and
speculate about the underlying genetic changes [1].
Based on progress that we have recently made in
understanding the genetics of the neoplastic pathogen-
esis of osteochondroma, and the multistep model
towards secondary chondrosarcoma, we would like to
supplement their article with some very recent data.
Based on the available literature, the authors
correctly conclude that a neoplastic pathogenesis for
osteochondroma should be suspected. In our opinion,
the most important support for a clonal origin of
osteochondroma lies in the clonal karyotypic abnorm-
alities described [2,3]. In support of this, we have
recently obtained data demonstrating loss of hetero-
zygosity (LOH) in the cartilaginous cap of 6 of 14
osteochondromas and DNA aneuploidy in 4 of 10
osteochondromas [4], strongly pointing towards a
clonal, and thus neoplastic, origin for the cartilaginous
tissue of osteochondroma. Although we understand
the temptation of Porter and Simpson to speculate that
the osteal part of osteochondroma may be considered
reactive tumour stroma, there are no data from
molecular or immunohistochemical studies available
from the literature to support this view. We feel that
further molecular genetic studies are required to
con®rm their statement.
To date, it is unclear whether complete inactivation
of an EXT gene (according to the Knudson tumour
suppressor model) is required for osteochondroma
development, or whether a single EXT germline
mutation acts in a dominant negative way, resulting
in multiple benign osteochondromas. In the latter,
inactivation of the remaining allele would be a
prerequisite for malignant transformation. The authors
propose ®ve speculative and, to us, unconvincing
arguments for a `dominant negative' effect of the
EXT tumour suppressor genes in hereditary multiple
exostoses. We describe two patients with multiple
osteochondromas demonstrating a germline EXT1
mutation [4]. This is combined with loss of the
remaining wild-type allele in three osteochondromas,
indicating that, in cartilaginous cells of the growth
plate, inactivation of both copies of the EXT1 gene is
required for osteochondroma formation in hereditary
cases [4]. This was also suggested by others [5] and
excludes a dominant negative effect of the EXT1 gene
in hereditary osteochondroma.
Their comparison of the `stepwise' process of
oncogenesis for the osteochondroma±chondrosarcoma
sequence to the colorectal adenoma±carcinoma
sequence (Table II [1]) is interesting, but requires
further comment. We do not believe that it is justi®ed
to subdivide osteochondroma into pre-neoplastic and
neoplastic categories, since there is now suf®cient
evidence that at least the cartilaginous cap of osteo-
chondroma is a true neoplasm. They correctly spec-
ulate that both copies of an EXT gene are inactivated,
which indicates neoplastic growth. Furthermore, there
is no indication that additional genetic alterations in
osteochondroma occur, since both cytogenetic studies
[2,3] and our own study [4] show alterations mainly
restricted to the EXT loci, especially EXT1.
We agree with the authors that in sporadic osteo-
chondroma, somatic inactivation of both copies of an
EXT gene could be expected. So far, only one somatic
mutation in the EXT1 gene has been described in a
sporadic chondrosarcoma [6]. We did not ®nd any
somatic EXT1 cDNA alterations in eight sporadic
osteochondromas and 14 sporadic chondrosarcomas.
Future studies on a larger panel of tumours should
reveal whether the situation is similar to the BRCA1
gene, for which only germline mutations in hereditary
breast cancer are described [7].
The authors' suggestion that progression to a low-
grade chondrosarcoma is accompanied by chromo-
some 3q and 10q deletion may be an oversimpli®ca-
tion. We compared LOH patterns of peripheral
chondrosarcomas secondary to osteochondromas with
those of primary central chondrosarcomas [8,9]. Nine-
teen of 20 peripheral chondrosarcomas showed LOH
at all loci tested (EXT genes, EXT-like genes, and at
9p21, 13q14, 17p13, and chromosome 10), while only 3
of 12 central chondrosarcomas exhibited LOH,
restricted to 9p21, 10, 13q14, and 17p13. DNA ¯ow
cytometry demonstrated a wide variation in the ploidy
status in peripheral chondrosarcomas (DNA indices
0.56±2.01), whereas central chondrosarcomas were
predominantly peridiploid. Remarkably, near-haploidy
was found in peripheral chondrosarcomas, which could
explain some of the high LOH percentages. Also,
polyploidization of a near-haploid clone had occurred
in two high-grade peripheral chondrosarcomas. In all
studies reported in the literature so far, no separation
has been made between central and peripheral chon-
drosarcoma; LOH data presented in this way should
therefore be interpreted with caution [8,9].
In conclusion, it seems to be more appropriate to
propose a genetic progression model for peripheral
cartilaginous tumourigenesis based on recently avail-
able data. First, inactivation of both copies of the
EXT1 gene in cartilaginous cells of the growth plate is
required for osteochondroma formation, as demon-
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strated by loss of the remaining wild-type allele in
hereditary osteochondromas [4]. Whether complete
inactivation occurs in sporadic cases remains to be
investigated. One or more additional genetic altera-
tions may then be required for a peripheral chondro-
sarcoma to arise within its benign precursor. The
process of malignant transformation is genetically
represented by chromosomal instability with severe
aneuploidy and a high LOH incidence in peripheral
chondrosarcoma [8,9].
Finally, in their discussion of the physiological
function of the EXT gene family, the authors omit the
important ®nding that an EXT1 homologue in Droso-
phila (tout-velu) was demonstrated to be required for
diffusion of the morphogen Hedgehog [10]. Remark-
ably, in humans, Indian Hedgehog is normally expressed
in the growth zone and pre-hypertrophic chondrocytes
of cartilage [11]. Furthermore, not only the EXT1 but
also the EXT2 gene products were shown to be
glycosyltransferases required for the biosynthesis of
heparan sulphate [12,13]. The role of the resulting
altered heparan sulphate expression on the cell surface
and the abnormal diffusion of Hedgehog within chon-
drocytes of the growth plate caused by EXT mutations
will be an interesting ®eld of study in the future, further
revealing the pathogenesis of osteochondroma.
Judith V. M. G. BoveÂe and Pancras C. W. Hogendoorn
Department of Pathology, Leiden University Medical Center,
P.O. Box 9600, L1-Q, 2300 RC Leiden, The Netherlands
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Authors' reply
We are grateful for the comments on our review from
Drs BoveÂe and Hogendoorn.
Our suggestion that the `osteal' part of the osteo-
chondroma may be reactive or supportive, rather than
truly neoplastic, re¯ects the surgical fact that ablation
of the cartilage cap alone will ablate further growth of
the osteochondroma.
We agree that it is unclear whether complete inacti-
vation of the EXT gene is required for osteochondroma
development. Despite this, our review emphasizes that
no research to date indicates any features of EXT
activity other than those which suggest a recessive
tumour suppressor gene function. Unfortunately, due
to an oversight in manuscript preparation for which we
apologize, we on one occasion describe the function of
the EXT gene as `dominant negative'. The ®ve features
which we attribute to EXT behaviour do, of course,
suppose an entirely `recessive' and not `dominant
negative' action of the gene.
Our review deals at length with the problems of
de®ning the cartilage cap of an osteochondroma as a
neoplasm on the traditional model. We justify our
classi®cation of the childhood osteochondroma, which
ossi®es at the end of skeletal growth, as `pre-neoplastic'
to overcome these traditional objections. We believe
that this is entirely consistent with the molecular data.
We agree that non-EXT gene changes have not been
identi®ed in osteochondromas in any signi®cant
number. Major genetic abnormalities would not be
expected to occur in simple `pre-neoplastic' childhood
osteochondromas. We suggest that reactivated, adult-
type osteochondromas, which are much less common,
would be the best candidates to investigate the
incidence of non-EXT genetic changes in accordance
with a step-wise model of osteochondroma±chondro-
sarcoma carcinogenesis.
D. E. Porter and A. H. R. W. Simpson
Nuf®eld Department of Orthopaedic Surgery, University of Oxford,
Headington, Oxford OX3 7LD, UK
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